4598 — Delta-Fly Pharma Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.9 | ||
| Price to Tang. Book | 6.9 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -252.87% | ||
| Return on Equity | -148.24% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 100 | 300 | 300 | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Delta-Fly Pharma, Inc. is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.
Directors
- Kiyoshi Eshima PRE (70)
- Kenichi Kurotaki DRC (56)
- Kenzo Iizuka DRC (58)
- Yasuo Matsueda DRC (61)
- Yoshihiko Bando IND (72)
- Sachio Kishii IND (42)
- Kinichiro Kominami IND (54)
- Akifumi Taniguchi IND (45)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 6th, 2010
- Public Since
- October 12th, 2018
- No. of Shareholders
- 5,486
- No. of Employees
- 13
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 9,729,702
- Address
- 37-5, Nishikino, Miyajima, Kawauchi-cho, TOKUSHIMA-SHI, 771-0116
- Web
- https://www.delta-flypharma.co.jp/
- Phone
- +81 362311278
- Auditors
- BDO Sanyu & Co.
Latest News for 4598
Upcoming Events for 4598
Full Year 2025 Delta-Fly Pharma Inc Earnings Release
Similar to 4598
ASKA Pharmaceutical Holdings Co
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings Co
Tokyo Stock Exchange
CanBas Co
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 20:12 UTC, shares in Delta-Fly Pharma are trading at ¥490. This share price information is delayed by 15 minutes.
Shares in Delta-Fly Pharma last closed at ¥490 and the price had moved by -38.83% over the past 365 days. In terms of relative price strength the Delta-Fly Pharma share price has underperformed the Nikkei 225 Index by -35.53% over the past year.
There is no consensus recommendation for this security.
Find out moreDelta-Fly Pharma does not currently pay a dividend.
Delta-Fly Pharma does not currently pay a dividend.
Delta-Fly Pharma does not currently pay a dividend.
To buy shares in Delta-Fly Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥490, shares in Delta-Fly Pharma had a market capitalisation of ¥5bn.
Here are the trading details for Delta-Fly Pharma:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4598
Based on an overall assessment of its quality, value and momentum Delta-Fly Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Delta-Fly Pharma. Over the past six months, its share price has outperformed the Nikkei 225 Index by +9.01%.
As of the last closing price of ¥490, shares in Delta-Fly Pharma were trading -14.05% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Delta-Fly Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥490.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Delta-Fly Pharma's management team is headed by:
- Kiyoshi Eshima - PRE
- Kenichi Kurotaki - DRC
- Kenzo Iizuka - DRC
- Yasuo Matsueda - DRC
- Yoshihiko Bando - IND
- Sachio Kishii - IND
- Kinichiro Kominami - IND
- Akifumi Taniguchi - IND